Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SkinHealth Systems Inc.SKIN · Entity 6863 | President, EMEA | February 04, 2022 | February 09, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SkinHealth Systems Inc.
Report date February 04, 2022 · Filed February 09, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 55,596 |
Reported balance
After 2022-02-04 transaction · row 1
1 source rowRow 1 · 2022-02-04 · Grant · Acquired 55,596 · Balance 55,596 F1: Represents a grant of restricted stock units that vest in one-third increments on each of the first three anniversaries of the grant date of February 4, 2022, in each case subject to continued service through the vesting date and certain acceleration rights. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units that vest in one-third increments on each of the first three anniversaries of the grant date of February 4, 2022, in each case subject to continued service through the vesting date and certain acceleration rights.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 04, 2022 Filed Feb 9, 2022 01:12 UTC | SkinHealth Systems Inc. SKIN · Entity 6863 | GrantClass A Common Stock | 55,596 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001818093-22-000027 · wf-form4_164436911052536.xml · nonDerivative · entry 1 Becker Stephan · CIK 0001886149 · President, EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,596 F1 · kind: Represents a grant of restricted stock units that vest in one-third increments on each of the first three anniversaries of the grant date of February 4, 2022, in each case subject to continued service through the vesting date and certain acceleration rights. F1 · price: Represents a grant of restricted stock units that vest in one-third increments on each of the first three anniversaries of the grant date of February 4, 2022, in each case subject to continued service through the vesting date and certain acceleration rights. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:02 UTC | SkinHealth Systems Inc. SKIN · Entity 6863 | GrantPerformance Restricted Stock Units · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001818093-21-000089 · wf-form4_163346770486433.xml · derivative · entry 2 Becker Stephan · CIK 0001886149 · President, EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Class A Common Stock · 50,000 shares Expires not disclosed F2 · derivative.exercise_price: Represents an award of performance-based restricted stock units that may be earned over a four-year performance period based on the achievement of performance goals related to the Company's stock price and continued employment with the Company through the end of the performance period. Each performance restricted stock unit converts on a one-for-one basis to Class A Common Stock upon vesting. F2 · price: Represents an award of performance-based restricted stock units that may be earned over a four-year performance period based on the achievement of performance goals related to the Company's stock price and continued employment with the Company through the end of the performance period. Each performance restricted stock unit converts on a one-for-one basis to Class A Common Stock upon vesting. F2 · derivative.exercise_date: Represents an award of performance-based restricted stock units that may be earned over a four-year performance period based on the achievement of performance goals related to the Company's stock price and continued employment with the Company through the end of the performance period. Each performance restricted stock unit converts on a one-for-one basis to Class A Common Stock upon vesting. F2 · derivative.expiration_date: Represents an award of performance-based restricted stock units that may be earned over a four-year performance period based on the achievement of performance goals related to the Company's stock price and continued employment with the Company through the end of the performance period. Each performance restricted stock unit converts on a one-for-one basis to Class A Common Stock upon vesting. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:02 UTC | SkinHealth Systems Inc. SKIN · Entity 6863 | GrantStock Options (right to buy) · Derivative | 372,000 | $0.00 Strike: $26.50 | $0.00 |
DisclosureSEC source: 0001818093-21-000089 · wf-form4_163346770486433.xml · derivative · entry 1 Becker Stephan · CIK 0001886149 · President, EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 372,000 Underlying: Class A Common Stock · 372,000 shares Expires 2031-10-01 F1 · derivative.exercise_date: Represents a grant of stock options that vest in increments of 25% on the first four anniversaries of October 1, 2021, subject to continued service through the vesting date and certain acceleration rights. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.